Eintrag weiter verarbeiten
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIE...
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| In: | Blood, 115, 2010, 16, S. 3206-3214 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Conter, Valentino Bartram, Claus R. Valsecchi, Maria Grazia Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Aricò, Maurizio Zimmermann, Martin Mann, Georg De Rossi, Giulio Stanulla, Martin Locatelli, Franco Basso, Giuseppe Niggli, Felix Barisone, Elena Henze, Günter Ludwig, Wolf-Dieter Haas, Oskar A. Cazzaniga, Giovanni Koehler, Rolf Silvestri, Daniela Bradtke, Jutta Parasole, Rosanna Beier, Rita van Dongen, Jacques J. M. Biondi, Andrea Schrappe, Martin Conter, Valentino Bartram, Claus R. Valsecchi, Maria Grazia Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Aricò, Maurizio Zimmermann, Martin Mann, Georg De Rossi, Giulio Stanulla, Martin Locatelli, Franco Basso, Giuseppe Niggli, Felix Barisone, Elena Henze, Günter Ludwig, Wolf-Dieter Haas, Oskar A. Cazzaniga, Giovanni Koehler, Rolf Silvestri, Daniela Bradtke, Jutta Parasole, Rosanna Beier, Rita van Dongen, Jacques J. M. Biondi, Andrea Schrappe, Martin |
|---|---|
| author |
Conter, Valentino Bartram, Claus R. Valsecchi, Maria Grazia Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Aricò, Maurizio Zimmermann, Martin Mann, Georg De Rossi, Giulio Stanulla, Martin Locatelli, Franco Basso, Giuseppe Niggli, Felix Barisone, Elena Henze, Günter Ludwig, Wolf-Dieter Haas, Oskar A. Cazzaniga, Giovanni Koehler, Rolf Silvestri, Daniela Bradtke, Jutta Parasole, Rosanna Beier, Rita van Dongen, Jacques J. M. Biondi, Andrea Schrappe, Martin |
| spellingShingle |
Conter, Valentino Bartram, Claus R. Valsecchi, Maria Grazia Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Aricò, Maurizio Zimmermann, Martin Mann, Georg De Rossi, Giulio Stanulla, Martin Locatelli, Franco Basso, Giuseppe Niggli, Felix Barisone, Elena Henze, Günter Ludwig, Wolf-Dieter Haas, Oskar A. Cazzaniga, Giovanni Koehler, Rolf Silvestri, Daniela Bradtke, Jutta Parasole, Rosanna Beier, Rita van Dongen, Jacques J. M. Biondi, Andrea Schrappe, Martin Blood Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Cell Biology Hematology Immunology Biochemistry |
| author_sort |
conter, valentino |
| spelling |
Conter, Valentino Bartram, Claus R. Valsecchi, Maria Grazia Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Aricò, Maurizio Zimmermann, Martin Mann, Georg De Rossi, Giulio Stanulla, Martin Locatelli, Franco Basso, Giuseppe Niggli, Felix Barisone, Elena Henze, Günter Ludwig, Wolf-Dieter Haas, Oskar A. Cazzaniga, Giovanni Koehler, Rolf Silvestri, Daniela Bradtke, Jutta Parasole, Rosanna Beier, Rita van Dongen, Jacques J. M. Biondi, Andrea Schrappe, Martin 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2009-10-248146 <jats:title>Abstract</jats:title> <jats:p>The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10−4); MRD high risk (MRD-HR) if 10−3 or more at day 78 and MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3). Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and NCT00613457 for AIEOP.</jats:p> Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Blood |
| doi_str_mv |
10.1182/blood-2009-10-248146 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Biologie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA5LTEwLTI0ODE0Ng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA5LTEwLTI0ODE0Ng |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Hematology, 2010 |
| imprint_str_mv |
American Society of Hematology, 2010 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
conter2010molecularresponsetotreatmentredefinesallprognosticfactorsinchildrenandadolescentswithbcellprecursoracutelymphoblasticleukemiaresultsin3184patientsoftheaieopbfmall2000study |
| publishDateSort |
2010 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_unstemmed |
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_full |
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_fullStr |
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_full_unstemmed |
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_short |
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_sort |
molecular response to treatment redefines all prognostic factors in children and adolescents with b-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the aieop-bfm all 2000 study |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2009-10-248146 |
| publishDate |
2010 |
| physical |
3206-3214 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10−4); MRD high risk (MRD-HR) if 10−3 or more at day 78 and MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3). Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and NCT00613457 for AIEOP.</jats:p> |
| container_issue |
16 |
| container_start_page |
3206 |
| container_title |
Blood |
| container_volume |
115 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347850867212299 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:01:50.404Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Molecular+response+to+treatment+redefines+all+prognostic+factors+in+children+and+adolescents+with+B-cell+precursor+acute+lymphoblastic+leukemia%3A+results+in+3184+patients+of+the+AIEOP-BFM+ALL+2000+study&rft.date=2010-04-22&genre=article&issn=1528-0020&volume=115&issue=16&spage=3206&epage=3214&pages=3206-3214&jtitle=Blood&atitle=Molecular+response+to+treatment+redefines+all+prognostic+factors+in+children+and+adolescents+with+B-cell+precursor+acute+lymphoblastic+leukemia%3A+results+in+3184+patients+of+the+AIEOP-BFM+ALL+2000+study&aulast=Schrappe&aufirst=Martin&rft_id=info%3Adoi%2F10.1182%2Fblood-2009-10-248146&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347850867212299 |
| author | Conter, Valentino, Bartram, Claus R., Valsecchi, Maria Grazia, Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Aricò, Maurizio, Zimmermann, Martin, Mann, Georg, De Rossi, Giulio, Stanulla, Martin, Locatelli, Franco, Basso, Giuseppe, Niggli, Felix, Barisone, Elena, Henze, Günter, Ludwig, Wolf-Dieter, Haas, Oskar A., Cazzaniga, Giovanni, Koehler, Rolf, Silvestri, Daniela, Bradtke, Jutta, Parasole, Rosanna, Beier, Rita, van Dongen, Jacques J. M., Biondi, Andrea, Schrappe, Martin |
| author_facet | Conter, Valentino, Bartram, Claus R., Valsecchi, Maria Grazia, Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Aricò, Maurizio, Zimmermann, Martin, Mann, Georg, De Rossi, Giulio, Stanulla, Martin, Locatelli, Franco, Basso, Giuseppe, Niggli, Felix, Barisone, Elena, Henze, Günter, Ludwig, Wolf-Dieter, Haas, Oskar A., Cazzaniga, Giovanni, Koehler, Rolf, Silvestri, Daniela, Bradtke, Jutta, Parasole, Rosanna, Beier, Rita, van Dongen, Jacques J. M., Biondi, Andrea, Schrappe, Martin, Conter, Valentino, Bartram, Claus R., Valsecchi, Maria Grazia, Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Aricò, Maurizio, Zimmermann, Martin, Mann, Georg, De Rossi, Giulio, Stanulla, Martin, Locatelli, Franco, Basso, Giuseppe, Niggli, Felix, Barisone, Elena, Henze, Günter, Ludwig, Wolf-Dieter, Haas, Oskar A., Cazzaniga, Giovanni, Koehler, Rolf, Silvestri, Daniela, Bradtke, Jutta, Parasole, Rosanna, Beier, Rita, van Dongen, Jacques J. M., Biondi, Andrea, Schrappe, Martin |
| author_sort | conter, valentino |
| container_issue | 16 |
| container_start_page | 3206 |
| container_title | Blood |
| container_volume | 115 |
| description | <jats:title>Abstract</jats:title> <jats:p>The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10−4); MRD high risk (MRD-HR) if 10−3 or more at day 78 and MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3). Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and NCT00613457 for AIEOP.</jats:p> |
| doi_str_mv | 10.1182/blood-2009-10-248146 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Biologie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDA5LTEwLTI0ODE0Ng |
| imprint | American Society of Hematology, 2010 |
| imprint_str_mv | American Society of Hematology, 2010 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T18:01:50.404Z |
| match_str | conter2010molecularresponsetotreatmentredefinesallprognosticfactorsinchildrenandadolescentswithbcellprecursoracutelymphoblasticleukemiaresultsin3184patientsoftheaieopbfmall2000study |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 3206-3214 |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Conter, Valentino Bartram, Claus R. Valsecchi, Maria Grazia Schrauder, André Panzer-Grümayer, Renate Möricke, Anja Aricò, Maurizio Zimmermann, Martin Mann, Georg De Rossi, Giulio Stanulla, Martin Locatelli, Franco Basso, Giuseppe Niggli, Felix Barisone, Elena Henze, Günter Ludwig, Wolf-Dieter Haas, Oskar A. Cazzaniga, Giovanni Koehler, Rolf Silvestri, Daniela Bradtke, Jutta Parasole, Rosanna Beier, Rita van Dongen, Jacques J. M. Biondi, Andrea Schrappe, Martin 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2009-10-248146 <jats:title>Abstract</jats:title> <jats:p>The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10−4); MRD high risk (MRD-HR) if 10−3 or more at day 78 and MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3). Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and NCT00613457 for AIEOP.</jats:p> Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Blood |
| spellingShingle | Conter, Valentino, Bartram, Claus R., Valsecchi, Maria Grazia, Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Aricò, Maurizio, Zimmermann, Martin, Mann, Georg, De Rossi, Giulio, Stanulla, Martin, Locatelli, Franco, Basso, Giuseppe, Niggli, Felix, Barisone, Elena, Henze, Günter, Ludwig, Wolf-Dieter, Haas, Oskar A., Cazzaniga, Giovanni, Koehler, Rolf, Silvestri, Daniela, Bradtke, Jutta, Parasole, Rosanna, Beier, Rita, van Dongen, Jacques J. M., Biondi, Andrea, Schrappe, Martin, Blood, Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_full | Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_fullStr | Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_full_unstemmed | Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_short | Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| title_sort | molecular response to treatment redefines all prognostic factors in children and adolescents with b-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the aieop-bfm all 2000 study |
| title_unstemmed | Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2009-10-248146 |